Filtered By:
Condition: Diabetes Type 2
Countries: Sweden Health
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 104 results found since Jan 2013.
Long ‐term excess risk of stroke in people with Type 2 diabetes in Sweden according to blood pressure level: a population‐based case–control study
ConclusionsPeople with Type 2 diabetes and blood pressure < 130/80 mmHg had a risk of stroke similar to that of the general population.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - November 24, 2016 Category: Endocrinology Authors: C. H. Stahl, M. Lind, A. ‐M. Svensson, M. Kosiborod, S. Gudbjörnsdottir, A. Pivodic, M. Clements, A. Rosengren Tags: Original Article Source Type: research
Estimating Insulin Resistance May Help Predict Stroke, Death in T2D Estimating Insulin Resistance May Help Predict Stroke, Death in T2D
Calculating the estimated glucose disposal rate as a proxy for the level of insulin resistance may be useful way to determine if someone with type 2 diabetes is at risk for having a first stroke, Swedish researchers have found.Medscape Medical News
Source: Medscape Medical News Headlines - October 21, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Medical News Today: Higher risk of stroke can follow midlife type 2 diabetes
A study of twins in Sweden links a 30% higher risk in older age of brain artery blockage, which stroke often follows, to type 2 diabetes in middle age.
Source: Health News from Medical News Today - June 12, 2019 Category: Consumer Health News Tags: Diabetes Type 2 Source Type: news
Blood-thinning drugs may reduce dementia risk in people with irregular heartbeats
Conclusion
If you’ve been diagnosed with AF and you have been prescribed anticoagulant treatments such as warfarin or clopidogrel, we already know they protect you against having a stroke. This study suggests they may also help to protect you against dementia.
Cutting the risk of dementia for people who have a raised risk because of AF would be an exciting step forward. Unfortunately, we can’t tell from this study whether the protection against dementia was down to the anticoagulants, because of the possible effect of unmeasured confounding factors.
Usually, we would want to see a randomised controlled trial (RCT) to f...
Source: NHS News Feed - October 25, 2017 Category: Consumer Health News Tags: Neurology Source Type: news
High Blood Pressure and Diabetes Are Linked. Here ’ s How to Reduce Your Risk for Both
High blood pressure—also known as hypertension—and Type 2 diabetes are two of the most common medical conditions in the U.S. Unfortunately, they often occur together. Some research has found that 85% of middle-aged or older adults who have Type 2 diabetes also have hypertension, and both conditions elevate a person’s risk for heart disease, stroke, and kidney disease.
These increased risks are significant, and in some cases grave. Researchers have found that people with Type 2 diabetes are up to four times more likely to develop cardiovascular disease than those who don’t have the conditio...
Source: TIME: Health - August 29, 2022 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Disease freelance healthscienceclimate Source Type: news
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Publication date: Available online 3 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson, Johan Bodegård, Anna Norhammar Background In patients with type 2 diabetes and a high cardiovascular risk profile, the sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower cardiovascular morbidity and mortality. Using real-world data from clinical practice, we aimed to compare cardiovas...
Source: The Lancet Diabetes and Endocrinology - August 4, 2017 Category: Endocrinology Source Type: research
How People With Type 2 Diabetes Can Lower Their Risk of Health Problems
A growing number of studies suggest that getting a handle on a few key risk factors can bring type 2 diabetes under control. Lowering blood sugar, for instance, reduces the risk of additional health problems, such as heart disease and stroke related to the disease.
But most of these studies have focused on studying one risk factor — like blood sugar, cholesterol or blood pressure — at a time. In a new study published in the New England Journal of Medicine, researchers analyzed what happens to death rates and other health problems when people control up to five known risk factors for type 2 diabetes.
The study ...
Source: TIME: Health - August 15, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthytime medicine Source Type: news
Circulating TNFrII levels predict incidence of ischemic heart disease and total mortality, independently of intima media thickness and pulse wave velocity in male with type 2 diabetes
AbstractNew and clinically useful markers of cardiovascular risk are of great importance in patients with type 2 diabetes since cardiovascular disease is a major cause of death in these patients. We analyzed inflammatory markers and other risk factors for heart disease in 761 patients who participated in the CARDIPP-study, Cardiovascular Risk factors in Patients with Diabetes —a Prospective study in Primary care. All participants had type 2 diabetes and were 55–66 years old at recruitment during the years 2005–2008. Patients were followed for incidence of stroke, myocardial infarction, or death from cardiovascular d...
Source: Heart and Vessels - August 21, 2021 Category: Cardiology Source Type: research
Dapagliflozin Compared to DPP ‐4 inhibitors is Associated with Lower Risk of Cardiovascular Events and All‐cause Mortality in Type 2 Diabetes Patients (CVD‐REAL Nordic): a multinational observational study
ConclusionsDapagliflozin was associated with lower risks of cardiovascular events and all‐cause mortality compared to DPP‐4i in a in a real‐world clinical setting and broad T2D population.
Source: Diabetes, Obesity and Metabolism - August 1, 2017 Category: Endocrinology Authors: F Persson, T Nystr öm, M E Jørgensen, B Carstensen, H L Gulseth, M Thuresson, P Fenici, D Nathanson, J W Eriksson, A Norhammar, J Bodegard, K I Birkeland Tags: ORIGINAL ARTICLE Source Type: research
Dapagliflozin is associated with lower risk of cardiovascular events and all ‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study
ConclusionsDapagliflozin was associated with lower risks of CV events and all‐cause mortality compared with DPP‐4 inhibitors in a real‐world clinical setting and a broad T2D population.
Source: Diabetes, Obesity and Metabolism - September 8, 2017 Category: Endocrinology Authors: Frederik Persson, Thomas Nystr öm, Marit E. Jørgensen, Bendix Carstensen, Hanne L. Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Jan W. Eriksson, Anna Norhammar, Johan Bodegard, Kåre I. Birkeland Tags: ORIGINAL ARTICLE Source Type: research
Long-Term Exposure to Transportation Noise in Relation to Development of Obesity —a Cohort Study
Conclusion:
Our results link transportation noise exposure to development of obesity and suggest that combined exposure from different sources may be particularly harmful. https://doi.org/10.1289/EHP1910
Received: 17 March 2017
Revised: 5 October 2017
Accepted: 9 October 2017
Published: 20 November 2017
Address correspondence to A. Pyko, Institute of Environmental Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden. Telephone: 46(0) 852487561. Email: Andrei.pyko@ki.se
Supplemental Material is available online (https://doi.org/10.1289/EHP1910).
The authors declare they have no actual or potential competing fina...
Source: EHP Research - November 20, 2017 Category: Environmental Health Authors: Daniil Lyalko Tags: Research Source Type: research
Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden
Publication date: Available online 5 December 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Henrik Svanström, Peter Ueda, Mads Melbye, Björn Eliasson, Ann-Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Björn PasternakSummaryBackgroundTrial evidence shows that the glucagon-like peptide-1 receptor agonist liraglutide significantly reduces the risk of major cardiovascular events among patients with type 2 diabetes who have established cardiovascular disease or are at high cardiovascular risk. We aimed to assess the cardiovascular effectiveness of liraglutide in rou...
Source: The Lancet Diabetes and Endocrinology - December 6, 2018 Category: Endocrinology Source Type: research
Editorial: Telomeres and Epigenetics in Endocrinology
This study was hypothesis-driven; the genetic variants were selected for being previously and substantially genotyped. The big sample size and the rich panel of other biomarkers allowed the authors to conduct much more detailed analyses on this topic.
The third article by Provenzi et al. proposed their perspectives on the role of telomeres in premature birth and discussed the potential implications for early adversity and care in the neonatal intensive care unit (Pavanello et al.). Indeed, the speculation of telomeres in aging begins in the premature aging syndrome. It is thus interesting to examine if telomeres also play...
Source: Frontiers in Endocrinology - April 23, 2019 Category: Endocrinology Source Type: research
Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus
ConclusionCardiovascular disease-free life expectancy and effects of lifelong prevention in terms of CVD-free life-years gained can be estimated for people with T2DM using readily available clinical characteristics. Predictions of individual-level treatment effects facilitate translation of trial results to individual patients.
Source: European Heart Journal - January 9, 2019 Category: Cardiology Source Type: research
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Diabetes Metab. 2023 Jan 3:101418. doi: 10.1016/j.diabet.2022.101418. Online ahead of print.ABSTRACTBACKGROUND: Continued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to similar therapies.METHODS: The EMPRISE Europe and Asia study is a non-interventional cohort study using data from 2014-2019 in seven European (Denmark, Finland, Germany, Norway, Spain, Sweden, United Kingdom) and four Asian (Israel, Japan, South Korea, Taiwan) countries. Patients with type 2 d...
Source: Diabetes and Metabolism - January 7, 2023 Category: Endocrinology Authors: Avraham Karasik Stefanie Lanzinger Elise Chia-Hui Tan Daisuke Yabe Dae Jung Kim Wayne H-H Sheu Cheli Melzer-Cohen Reinhard W Holl Kyoung Hwa Ha Kamlesh Khunti Francesco Zaccardi Anuradhaa Subramanian Krishnarajah Nirantharakumar Thomas Nystr öm Leo Niska Source Type: research
